疏水性相互作用主导了KRAS G12V新抗原的识别
Katharine M Wright1,2,3,4, Sarah R DiNapoli2,5,6, Michelle S Miller1,2,3,7
1Department of Biophysics and Biophysical Chemistry, The Johns Hopkins School of Medicine, Baltimore, MD, 21205, USA.
Nature communications
|August 21, 2023
概括
这项研究揭示了抗体如何能够向癌症特异性突变相关新抗原 (MANAs). 结构分析确定了疏水性相互作用是区分突变KRAS与正常的关键,用于癌症治疗.
科学领域:
- 结构生物学 结构生物学
- 免疫学 免疫学 免疫学
- 癌症治疗方法 癌症治疗方法
背景情况:
- 癌症治疗面临着特殊性挑战,突出了针对性治疗的需要.
- 突变相关的新抗原 (MANAs) 由于癌细胞的遗传变化而提供了特定的点.
- MANA是由HLA分子呈现的,这使得它们成为免疫疗法的潜在目标.
研究的目的:
- 确定对突变相关新抗原 (MANAs) 的抗体识别的结构基础.
- 为了研究分子相互作用,使得突变和野生类型之间有区别.
- 为开发基于抗体的新型癌症疗法提供结构性基础.
主要方法:
- 使用冷电子显微镜 (cryo-EM) 来确定与HLA-A*03:01.01呈现的MANA结合的TCR模仿抗体的结构.
- 使用X射线结晶学来确定与HLA-A*03:01.1结合的野生类型的结构.
- 进行了功能性选,以验证特定残留物在识别中的作用.
主要成果:
- 冷-EM结构揭示了一个与KRASG12V MANA结合的TCR模仿抗体,由HLA-A*03:01.01呈现.
- 鉴定出疏水性相互作用是G12V突变特异性的关键决定因素.
- 结构和实验数据阐明了一个基于疏水相互作用的模型来区分突变与野生类型.
结论:
- 对MANA pHLA复合体的抗体识别可以由特定的疏水性相互作用驱动.
- 了解这些相互作用使得能够设计针对突变的高度特定的癌症治疗方法.
- 这项工作为开发针对 KRAS 突变癌症的向免疫疗法提供了结构性基础.
更多相关视频
09:53Using X-ray Crystallography, Biophysics, and Functional Assays to Determine the Mechanisms Governing T-cell Receptor Recognition of Cancer Antigens
Published on: February 6, 2017
11.5K
07:08Fully Processed Recombinant KRAS4b: Isolating and Characterizing the Farnesylated and Methylated Protein
Published on: January 16, 2020
5.7K
相关概念视频
Small GTPases - Ras and Rho
4.0K
Ras and Rho are small monomeric GTPases that act downstream of receptor tyrosine kinase (RTK) and regulate various cellular processes. These GTPases switch between active and inactive states by binding to guanine nucleotides.
Three regulatory proteins control their activity:
Three regulatory proteins control their activity:
4.0K
Antigens Involved in Adaptive Immunity
538
An antigen is any substance the immune system identifies as foreign and potentially harmful to the body, prompting an immune response. Antigens have two functional properties: immunogenicity and reactivity. Immunogenicity is the ability of an antigen to stimulate a specific immune response. At the same time, reactivity describes the antigen's ability to react with the cells and antibodies produced in response to it.
Complete Antigens
Complete antigens possess both immunogenicity and...
Complete Antigens
Complete antigens possess both immunogenicity and...
538
